Press Releases

 
Press Releases
Date Title and Summary View
May 18, 2017 SALT LAKE CITY, May 18, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and perso...
May 12, 2017 SALT LAKE CITY, May 12, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnost...
May 5, 2017 SALT LAKE CITY, May 05, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today ...
May 2, 2017 Third-Quarter 2017 Total Revenues of $196.9 MillionThird-Quarter 2017 GAAP Diluted EPS of $0.06 and Adjusted EPS of $0.27Company Increases Annual Revenue Guidance, Narrows Adjusted EPS Guidance SALT LAKE CITY, May 02, 2017 (GLOBE NEWSWIRE) -- Myria...
Apr 27, 2017
Apr 18, 2017 SALT LAKE CITY, April 18, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) today announced that it will hold its fiscal third-quarter 2017 sales and earnings conference call with investors and analysts at 4:30 p.m. ET on Tuesday, May 2, 2017.  During the call, Mark C. Capone, president and CEO and Bryan Riggsbee...
Apr 17, 2017 SALT LAKE CITY, April 17, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, t...
Apr 6, 2017 SALT LAKE CITY, April 06, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, toda...
Apr 5, 2017 SALT LAKE CITY, April 05, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular dia...
Mar 20, 2017 SALT LAKE CITY, March 20, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, toda...
Page: FirstPrevious
4
... NextLast
= add release to Briefcase